Bristol-Myers Squibb Co - Company Profile
Powered by
All the data and insights you need on Bristol-Myers Squibb Co in one report.
- Save hours of research time and resources with
our up-to-date Bristol-Myers Squibb Co Strategy Report
- Understand Bristol-Myers Squibb Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
Bristol-Myers Squibb Co premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Cardiovascular Drugs | Abecma |
Diabetes Alliance Products | Abraxane |
Virology Drugs | Azactam |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company signed a US$380 million deal with Cellares to produce its CAR-T cell therapies in the US, EU, and Japan. |
2024 | Product Recall | In April, the company recalled OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) due to the product quality issue. |
2024 | Regulatory Approval | In April, the company received approval from the European Commission for Reblozyl (luspatercept) as a treatment for adults with transfusion-dependent anaemia. |
Competitor Comparison
Key Parameters | Bristol-Myers Squibb Co | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
City | Princeton | New Brunswick | Kenilworth | Paris | Basel |
State/Province | New Jersey | New Jersey | New Jersey | Ile-de-France | - |
No. of Employees | 34,100 | 131,900 | 72,000 | 87,994 | 76,057 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Christopher S. Boerner Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2024 | - |
David V. Elkins | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 55 |
Paul von Autenried | Executive Vice President; Chief Information Officer | Senior Management | 2019 | 60 |
Amanda Poole | Chief Human Resources Officer; Executive Vice President | Senior Management | 2024 | 58 |
Adam Lenkowsky | Chief Commercialization Officer; Executive Vice President | Senior Management | 2023 | 52 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer